Melbourne, Feb 25, 2009 (ABN Newswire) - Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced successful achievement of the key safety milestone in the first low-dose cohort of patients treated with Revascor(tm), the proprietary allogeneic, or "off-the-shelf", universal adult stem cell product for congestive heart failure.